WEDNESDAY, MARCH 3, 2021 | MARKETBEAT
Equities analysts predict that Exelixis, Inc. (NASDAQ:EXEL) will announce sales of $268.93 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Exelixis' earnings. The highest sales estimate is $304.36 million and the lowest is $255.02 million. Exelixis reported sales of $226.92 million during the same quarter last year, which indicates a positive year-over-year growth rate of 18.5%. The firm is expected to announce its next quarterly earnings report on Tuesday, May 4th.
On average, analysts expect that Exelixis will report full-year sales of $1.23 billion for the current year, with estimates ranging from $1.15 billion to $1.35 billion. For the next year, analysts expect that the business will report sales of $1.65 billion, with estimates ranging from $1.48 billion to $1.82 billion. Zacks' sales averages are an average based on a survey of sell-side research analysts that cover Exelixis.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 9th. The biotechnology company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.05 by $0.04. The company had revenue of $270.10 million for the quarter, compared to the consensus estimate of $261.44 million. Exelixis had a return on equity of 8.55% and a net margin of 15.88%. The firm's revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share.
A number of equities analysts recently commented on the stock. Morgan Stanley lowered their price target on shares of Exelixis from $29.00 to $27.00 and set an "equal weight" rating on the stock in a research report on Wednesday, December 16th. William Blair restated a "buy" rating on shares of Exelixis in a research note on Friday, January 15th. Piper Sandler upped their target price on Exelixis from $33.00 to $36.00 and gave the company an "overweight" rating in a research report on Tuesday, February 16th. Finally, TheStreet upgraded Exelixis from a "c" rating to a "b-" rating in a research report on Wednesday, February 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of "Buy" and a consensus price target of $31.50.